Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 11/20 | 0.41 |
| ▸ | RAB9A | P51151 | 11/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.39 |
| ▸ | EP300 | Q09472 | 1/20 | 0.38 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.38 |
| ▸ | SELE | P16581 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11971241 | 0.88 | NPC1 (0.43) | KMT2AMEN1NPC1RAB9APOLB | |
| SCHEMBL1808138 | 0.87 | MEN1 (0.49) | KMT2AMEN1NPC1RAB9ACREBBP | |
| SCHEMBL7475630 | 0.84 | NPC1 (0.42) | KMT2AMEN1NPC1RAB9APOLB | |
| SCHEMBL15931905 | 0.82 | RAB9A (0.41) | KMT2AMEN1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL22275507 | 0.81 | KDM4C (0.41) | KMT2AMEN1NPC1RAB9APOLB | |
| SCHEMBL24006643 | 0.80 | KDM4C (0.40) | KMT2AMEN1NPC1RAB9APOLB | |
| SCHEMBL1808675 | 0.79 | S1PR1 (0.45) | KMT2AMEN1NPC1RAB9APOLB | |
| SCHEMBL24015128 | 0.79 | KDM4C (0.42) | KMT2AMEN1NPC1RAB9APOLB | |
| SCHEMBL1808415 | 0.79 | MEN1 (0.42) | KMT2AMEN1NPC1RAB9APOLB | |
| SCHEMBL24006607 | 0.78 | KDM4C (0.41) | KMT2AMEN1NPC1RAB9ACREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3388433-B1 | PHTHALAZINE DERIVATIVES, AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | SHANGHAI SIMR BIOTECH CO LTD (CN) | 2023-08-30 | — | — | EP | disclosed |
| EP-3388433-B1 | PHTHALAZINE DERIVATIVES, AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | SHANGHAI SIMR BIOTECH CO LTD (CN) | 2023-08-30 | — | — | EP | disclosed |
| US-11220503-B2 | Phthalazine derivatives, preparation method, pharmaceutical composition and usage thereof | SHANGHAI SIMR BIOTECH CO., LTD. (CN) | 2022-01-11 | — | — | US | disclosed |
| US-11220503-B2 | Phthalazine derivatives, preparation method, pharmaceutical composition and usage thereof | SHANGHAI SIMR BIOTECH CO., LTD. (CN) | 2022-01-11 | — | — | US | disclosed |
| US-20200165253-A1 | Phthalazine Derivatives, Preparation Method, Pharmaceutical Composition and Usage Thereof | SHANGHAI SIMRD BIOTECHNOLOGY. CO., LTD. (CN) | 2020-05-28 | — | — | US | disclosed |
| US-20200165253-A1 | Phthalazine Derivatives, Preparation Method, Pharmaceutical Composition and Usage Thereof | SHANGHAI SIMRD BIOTECHNOLOGY. CO., LTD. (CN) | 2020-05-28 | — | — | US | disclosed |
| EP-3388433-A1 | PHTHALAZINE DERIVATIVES, AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | Shanghai Simr Biotech Co., Ltd (CN) | 2018-10-17 | — | — | EP | disclosed |
| WO-2017097217-A1 | PHTHALAZINE DERIVATIVES, AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | 上海赛默罗生物科技有限公司 | 2017-06-15 | — | — | WO | disclosed |
| EP-0986562-B1 | SUBSTITUTED 1,2,4-TRIAZOLO 3,4-A]PHTHALAZINE DERIVATIVES AS GABA ALPHA 5 LIGANDS | MERCK SHARP & DOHME (GB) | 2002-08-07 | — | — | EP | disclosed |
| US-6310203-B1 | Precursor compounds to substituted 1,2,4-triazolo[3,4,-a]phathalazine GABA alpha 5 ligands | MERCK SHARPE & DOHME LIMITED (GB) | 2001-10-30 | — | — | US | disclosed |
| US-6200975-B1 | FOR COGNITION ENHANCEMENT THERAPY | MERCK SHARP & DOHME LIMITED (GB) | 2001-03-13 | — | — | US | disclosed |
| EP-0986562-A1 | SUBSTITUTED 1,2,4-TRIAZOLO 3,4-A]PHTHALAZINE DERIVATIVES AS GABA ALPHA 5 LIGANDS | MERCK SHARP & DOHME LTD. (GB) | 2000-03-22 | — | — | EP | disclosed |
| WO-1998050385-A1 | SUBSTITUTED 1,2,4-TRIAZOLO[3,4-a]PHTHALAZINE DERIVATIVES AS GABA ALPHA 5 LIGANDS | MERCK SHARP & DOHME LIMITED (GB) | 1998-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11220503-B2 | Phthalazine derivatives, preparation method, pharmaceutical composition and usage thereof | GABRA5, CYP3A5, GABRA1 | KMT2A 2164/4885MEN1 2724/4885NPC1 1345/4885 |
| US-20200165253-A1 | Phthalazine Derivatives, Preparation Method, Pharmaceutical Composition and Usage Thereof | GABRA5, CYP3A5, GABRA1 | KMT2A 2164/4885MEN1 2724/4885NPC1 1345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.